The HSP60 level is context-dependent and also depends on the types of cancer and tissues as compared to normal tissue, thus targeting HSP60 may be a potential candidate to reduce both the adverse effects and drug resistance in many tumor and cancer cells [212,213]. This evidence concerns the gene HSPD1 and neoplasm.